Teva Gains FDA Nod for Once-Monthly Schizophrenia Treatment WELTRUZA
Event summary
- Teva's WELTRUZA (olanzapine) received FDA approval on October 9, 2026, as the first once-monthly subcutaneous injectable for schizophrenia.
- The approval is based on Phase 3 SOLARIS trial results showing symptom improvement, reduced illness severity, and better personal/social functioning.
- WELTRUZA will be available in three strengths (318 mg, 425 mg, 531 mg) with no loading doses or post-injection monitoring required.
- Teva's proprietary SteadyTeq™ technology enables controlled, sustained release of olanzapine.
The big picture
Teva's FDA approval for WELTRUZA underscores its strategic pivot toward neuroscience innovation, addressing a critical gap in schizophrenia treatment adherence. The once-monthly subcutaneous formulation could disrupt the long-acting injectable market, where adherence challenges have historically limited treatment efficacy. This approval aligns with Teva's broader 'Pivot to Growth' strategy, which emphasizes expanding its innovative and biosimilar medicines pipeline.
What we're watching
- Market Differentiation
- Whether WELTRUZA can carve out a distinct niche in the competitive schizophrenia treatment landscape.
- Commercial Execution
- The pace at which Teva can scale WELTRUZA's commercial rollout and gain market share.
- Regulatory Momentum
- The timeline for potential EMA approval, which could expand WELTRUZA's market reach.
Related topics
